Another vaccine hopeful is joining the fight against Ebola. Inovio Pharmaceuticals said this week that it will move its Ebola vaccine candidate into clinical trials in the first half of 2015.
Having begun the month by revealing new problems at its Canadian flu vaccine plant and followed that up with a fine for violating the U.S. Clean Air Act last week, GSK has now accidentally dumped live poliovirus into the Belgian sewer system.
As the death toll of West Africa's Ebola outbreak reaches 2,500, GlaxoSmithKline's experimental Ebola vaccine is being tested at the U.S. National Institutes of Health with no apparent ill effects so far, health officials report.
Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.
Two lawsuits claiming Merck lied about the efficacy of its mumps vaccine won't be going away anytime soon. A federal judge in Pennsylvania refused to dismiss the suits, filed by a pair of whistleblowers and a group of doctors and payers, and now, they're on their way to trial.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
Looking back on data from old pediatric HIV vaccine trials, researchers have found that two vaccines studied in the 1990s elicited a specific antibody response that was unknown at the time to be associated with HIV protection.
Though polio has been nearly eradicated from the globe, researchers have made a troubling discovery that underscores the need to boost vaccination rates in countries that have seen recent outbreaks as well as develop new, more potent vaccines.
As the Ebola outbreak continues to claim victims in West Africa, governments and industry alike are racing toward a therapeutic or preventive drug that could help halt its deadly spread and avert future human crises involving the virus.
As the U.S. continues to experience the highest number of measles cases this year since the highly contagious viral illness was eliminated nationwide in 2000, health officials and researchers are looking for ways to keep vaccination rates in check.